AbbVie Japan is launching the Innovation Award in collaboration with BioLabs. The award consists of one Golden Ticket and a cash prize of 10 Million yen. The Golden ticket provides one year of fully paid individual bench and membership at one of BioLabs’ facilities in Japan. The award is intended for Japanese early-stage biotech companies focused on science / technology with potential to generate transformational therapies that align strategically with AbbVie’s therapeutic areas of interest, including immunology, oncology, neuroscience, eye care, obesity, and aesthetics. Additional eligibility requirements are listed below.

AbbVie Japan is launching the Innovation Award in collaboration with BioLabs. The award consists of One Golden ticket and a cash prize of 10 Million yen. The Golden ticket provides one year of fully paid individual bench and membership at one of BioLabs’ facilities in Japan. The award is intended for Japanese early-stage biotech companies focused on science / technology with potential to generate transformational therapies that align strategically with AbbVie’s therapeutic areas of interest, including immunology, oncology, neuroscience, eye care, obesity, and aesthetics. Additional eligibility requirements are listed below.AbbVie Japan is launching the Innovation Award in collaboration with BioLabs. The award consists of One Golden ticket and a cash prize of 10 Million yen. The Golden ticket provides one year of fully paid individual bench and membership at one of BioLabs’ facilities in Japan. The award is intended for Japanese early-stage biotech companies focused on science / technology with potential to generate transformational therapies that align strategically with AbbVie’s therapeutic areas of interest, including immunology, oncology, neuroscience, eye care, obesity, and aesthetics. Additional eligibility requirements are listed below.